Cargando…
(1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug
(1)H high resolution magic angle spinning (HR-MAS) NMR spectroscopy was applied in combination with multivariate statistical analyses to study the metabolic response of whole cells to the treatment with a hexacationic ruthenium metallaprism [1](6+) as potential anticancer drug. Human ovarian cancer...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449131/ https://www.ncbi.nlm.nih.gov/pubmed/26024484 http://dx.doi.org/10.1371/journal.pone.0128478 |
_version_ | 1782373816388812800 |
---|---|
author | Vermathen, Martina Paul, Lydia E. H. Diserens, Gaëlle Vermathen, Peter Furrer, Julien |
author_facet | Vermathen, Martina Paul, Lydia E. H. Diserens, Gaëlle Vermathen, Peter Furrer, Julien |
author_sort | Vermathen, Martina |
collection | PubMed |
description | (1)H high resolution magic angle spinning (HR-MAS) NMR spectroscopy was applied in combination with multivariate statistical analyses to study the metabolic response of whole cells to the treatment with a hexacationic ruthenium metallaprism [1](6+) as potential anticancer drug. Human ovarian cancer cells (A2780), the corresponding cisplatin resistant cells (A2780cisR), and human embryonic kidney cells (HEK-293) were each incubated for 24 h and 72 h with [1](6+) and compared to untreated cells. Different responses were obtained depending on the cell type and incubation time. Most pronounced changes were found for lipids, choline containing compounds, glutamate and glutathione, nucleotide sugars, lactate, and some amino acids. Possible contributions of these metabolites to physiologic processes are discussed. The time-dependent metabolic response patterns suggest that A2780 cells on one hand and HEK-293 cells and A2780cisR cells on the other hand may follow different cell death pathways and exist in different temporal stages thereof. |
format | Online Article Text |
id | pubmed-4449131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-44491312015-06-09 (1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug Vermathen, Martina Paul, Lydia E. H. Diserens, Gaëlle Vermathen, Peter Furrer, Julien PLoS One Research Article (1)H high resolution magic angle spinning (HR-MAS) NMR spectroscopy was applied in combination with multivariate statistical analyses to study the metabolic response of whole cells to the treatment with a hexacationic ruthenium metallaprism [1](6+) as potential anticancer drug. Human ovarian cancer cells (A2780), the corresponding cisplatin resistant cells (A2780cisR), and human embryonic kidney cells (HEK-293) were each incubated for 24 h and 72 h with [1](6+) and compared to untreated cells. Different responses were obtained depending on the cell type and incubation time. Most pronounced changes were found for lipids, choline containing compounds, glutamate and glutathione, nucleotide sugars, lactate, and some amino acids. Possible contributions of these metabolites to physiologic processes are discussed. The time-dependent metabolic response patterns suggest that A2780 cells on one hand and HEK-293 cells and A2780cisR cells on the other hand may follow different cell death pathways and exist in different temporal stages thereof. Public Library of Science 2015-05-29 /pmc/articles/PMC4449131/ /pubmed/26024484 http://dx.doi.org/10.1371/journal.pone.0128478 Text en © 2015 Vermathen et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Vermathen, Martina Paul, Lydia E. H. Diserens, Gaëlle Vermathen, Peter Furrer, Julien (1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug |
title |
(1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug |
title_full |
(1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug |
title_fullStr |
(1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug |
title_full_unstemmed |
(1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug |
title_short |
(1)H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug |
title_sort | (1)h hr-mas nmr based metabolic profiling of cells in response to treatment with a hexacationic ruthenium metallaprism as potential anticancer drug |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449131/ https://www.ncbi.nlm.nih.gov/pubmed/26024484 http://dx.doi.org/10.1371/journal.pone.0128478 |
work_keys_str_mv | AT vermathenmartina 1hhrmasnmrbasedmetabolicprofilingofcellsinresponsetotreatmentwithahexacationicrutheniummetallaprismaspotentialanticancerdrug AT paullydiaeh 1hhrmasnmrbasedmetabolicprofilingofcellsinresponsetotreatmentwithahexacationicrutheniummetallaprismaspotentialanticancerdrug AT diserensgaelle 1hhrmasnmrbasedmetabolicprofilingofcellsinresponsetotreatmentwithahexacationicrutheniummetallaprismaspotentialanticancerdrug AT vermathenpeter 1hhrmasnmrbasedmetabolicprofilingofcellsinresponsetotreatmentwithahexacationicrutheniummetallaprismaspotentialanticancerdrug AT furrerjulien 1hhrmasnmrbasedmetabolicprofilingofcellsinresponsetotreatmentwithahexacationicrutheniummetallaprismaspotentialanticancerdrug |